Text Size

Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck

This study has been terminated.
(Insufficient Accrual)
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
USC/Norris Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00184028
First received: September 12, 2005
Last updated: March 21, 2013
Last verified: March 2013
History of Changes
  Purpose

This research study is for subjects with squamous cell cancer of the head and neck which is not solely treatable with surgery or radiation. This research study involves treatment with an experimental chemotherapy combination of oxaliplatin and Taxotere. Tha main purpose of this study is to assess the effectiveness of this combination of medications for this type of cancer.

Approximately 54 subjects will take part in this study.


Condition Intervention Phase
Carcinoma of the Head and Neck
 Drug: Taxotere
Drug: Oxaliplatin
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Taxotere and Oxaliplatin Combination Chemotherapy in Squamous Cell Carcinoma of the Head and Neck

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by USC/Norris Comprehensive Cancer Center:

Primary Outcome Measures:
  • Tumor Response [ Time Frame: 6 months after the last subject enrolled has gone off study ] [ Designated as safety issue: No ]

    All eligible patients who received the first dose of Taxotere will be included in the analysis.

    Tumor Response will be categorized as: Complete Response, Partial Response, Stable Disease, Progressive Disease, Early Death from Malignant Disease, Early Death from Toxicity, Early Death Because of Other Cause, Unknown (not assessable, insufficient data), or Never Received Any of the Drugs, Taxotere or Oxaliplatin.



Secondary Outcome Measures:
  • Number of Participants With Serious Adverse Events (SAEs) [ Time Frame: At end of every cycle ] [ Designated as safety issue: Yes ]
    Safety evaluation according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.


Enrollment: 12
Study Start Date: September 2004
Study Completion Date: July 2010
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
On Day 1 of each day treatment cycle, patients receive Taxotere 60 mg/m2 as a 1-hour IV infusion, followed by the administration of oxaliplatin 100 mg/m2. Oxaliplatin will be administered IV over 2 hours at a rate of 10mg/m2/min. This treatment regimen will be repeated every 21 days.
 Drug: Taxotere
Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
Drug: Oxaliplatin
Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed Head and Neck Squamous Cell Carcinoma which is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
  • Tissue from tumor must be available. This may be paraffin embedded tissue from previous biopsy/resection. If it is not available, a repeat biopsy must be performed.
  • Age greater than or equal to 18 years
  • ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 50%)
  • Patients must have adequate organ and marrow function as defined below:
  • leukocytes greater than or equal to 3,000/microliter
  • hemoglobin greater than or equal to 8.0 g/dl
  • absolute neutrophil count greater than or equal to 1,500/microliter
  • platelets greater than or equal to 100,000/microliter
  • total bilirubin within normal institutional limits
  • creatinine within normal institutional limits OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal

  • If:

    • ALK PHOS is less than or equal to ULN and AST or ALT is less than or equal to ULN, patient is eligible.
    • ALK PHOS is less than or equal to ULN and AST or ALT is greater than 1x but less than or equal to 1.5x, patient is eligible.
    • ALK PHOS is less than or equal to ULN and AST or ALT is greater than 1.5x but less than or equal to 5x, patient is eligible.
    • ALK PHOS is less than or equal to ULN and AST or ALT is greater than 5x ULN, patient is ineligible.
    • ALK PHOS is greater than 1x but less than or equal to 2.5x and AST or ALT is less than or equal to ULN, patient is eligible.
    • ALK PHOS is greater than 1x but less than or equal to 2.5x and AST or ALT is greater than 1x but less than or equal to 1.5x, patient is eligible.
    • ALK PHOS is greater than 1x but less than or equal to 2.5x and AST or ALT is greater than 1.5x but less than or equal to 5x, patient is ineligible.
    • ALK PHOS is greater than 1x but less than or equal to 2.5x and AST or ALT is greater than 5x ULN, patient is ineligible.
    • ALK PHOS is greater than 2.5x but less than or equal to 5x and ALT or AST is less than or equal to ULN,patient is eligible.
    • ALK PHOS is greater than 2.5x but less than or equal to 5x and ALT or AST is greater than 1x but less than or equal to 1.5x, patient is ineligible.
    • ALK PHOS is greater than 2.5x but less than or equal to 5x and ALT or AST is greater than 1.5x but less than or equal to 5x, patient is ineligible.
    • ALK PHOS is greater than 2.5x but less than or equal to 5x and ALT or AST is greater than 5x ULN, patient is ineligible.
    • ALK PHOS is greater than 5x ULN and AST or ALT is less than or equal to ULN, patient is ineligible.
    • ALK PHOS is greater than 5x ULN and AST or ALT is greater than 1x but less than or equal to 1.5x, patient is ineligible
    • ALK PHOS is greater than 5x ULN and AST or ALT is greater than 1.5x but less than or equal to 5x, patient is ineligible
    • ALK PHOS is greater than 5x ULN and AST or ALT is greater than 5x ULN, patient is ineligible
  • Patients with neuropathy < 1.
  • Ability to understand and the willingness to sign a written informed consent document
  • Women of childbearing potential must have a negative pregnancy test
  • Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study
  • Patients undergoing therapy with other investigational agents.
  • Previous treatment involving regimen utilizing any of the protocol chemotherapeutic agents
  • Patients with known brain metastases
  • History of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy. Patients with a history of severe hypersensitivity reaction to Taxotere or Oxaliplatin or other drugs formulated with polysorbate 80
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, or unstable angina pectoris, or cardiac arrhythmia
  • Pregnant and nursing women
  • HIV-positive patients
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00184028

Locations
United States, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Sponsors and Collaborators
USC/Norris Comprehensive Cancer Center
Sanofi
Investigators
Principal Investigator: Barbara Gitlitz, MD University of Southern California
  More Information

No publications provided

Responsible Party: USC/Norris Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00184028     History of Changes
Other Study ID Numbers: 7H-03-1
Study First Received: September 12, 2005
Results First Received: March 21, 2013
Last Updated: March 21, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
 Neoplasms by Site
Oxaliplatin
Docetaxel
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 18, 2013